{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:55:18Z","timestamp":1772038518540,"version":"3.50.1"},"reference-count":4,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1111\/dth.12531","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T12:22:42Z","timestamp":1503058962000},"page":"e12531","source":"Crossref","is-referenced-by-count":5,"title":["Jak-inhibitors and UV-B: Potential combined therapy for vitiligo"],"prefix":"10.1155","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-5367","authenticated-orcid":false,"given":"Brittany","family":"Urso","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Central Florida College of Medicine; Orlando Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"10.1111\/dth.12531-BIB0001|dth12531-cit-0002","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: Focus on clinical aspects, immunopathogenesis, and therapy","author":"Boniface","year":"2017","journal-title":"Clinical Review of Allergy Immunology"},{"issue":"10","key":"10.1111\/dth.12531-BIB0002|dth12531-cit-0003","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1111\/dth.12531-BIB0003|dth12531-cit-0004","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"Journal of American Academy of Dermatology"},{"key":"10.1111\/dth.12531-BIB0004|dth12531-cit-0005","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2017.1339013","article-title":"Importance of light in the treatment of vitiligo with JAK-inhibitors","author":"Joshipura","year":"2017","journal-title":"Journal of Dermatological Treatment"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12531\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:01Z","timestamp":1671818221000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12531","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,18]]}}}